A61K 31/5025
Ortho- or peri-condensed with heterocyclic ring systems
Official title: ortho- or peri-condensed with heterocyclic ring systems
A61K31/5025 (Ortho- or peri-condensed with heterocyclic ring systems) appears on 751 US grants and 1,627 published applications in this corpus.
Search patents in A61K- Granted patents
- 751
- Published applications
- 1,627
- Assignees
- 728
- Inventors
- 4,439
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 4 | 0 |
| 1998 | 5 | 0 |
| 1999 | 3 | 0 |
| 2000 | 10 | 0 |
| 2001 | 4 | 0 |
| 2002 | 6 | 4 |
| 2003 | 3 | 18 |
| 2004 | 8 | 17 |
| 2005 | 3 | 11 |
| 2006 | 4 | 14 |
| 2007 | 3 | 10 |
| 2008 | 3 | 10 |
| 2009 | 7 | 21 |
| 2010 | 11 | 25 |
| 2011 | 14 | 41 |
| 2012 | 10 | 23 |
| 2013 | 27 | 55 |
| 2014 | 26 | 77 |
| 2015 | 45 | 82 |
| 2016 | 65 | 91 |
| 2017 | 63 | 76 |
| 2018 | 51 | 76 |
| 2019 | 56 | 84 |
| 2020 | 58 | 114 |
| 2021 | 42 | 101 |
| 2022 | 51 | 88 |
| 2023 | 36 | 111 |
| 2024 | 43 | 157 |
| 2025 | 46 | 190 |
| 2026 | 43 | 131 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- AP2 associated kinase 1 inhibitors and uses thereof29 Sep 2026US 12,747,245 B2Satellos Bioscience Inc.
- Macrocyclic derivative and use thereof15 Sep 2026US 12,734,177 B2Guangzhou Joyo Pharmatech Co., Ltd
- MALT-1 modulators8 Sep 2026US 12,729,201 B2Recursion Pharmaceuticals, Inc.
- Method and kit for determining benefit of chemotherapy8 Sep 2026US 12,729,405 B2St. Jude Children?S Research Hospital
- HER3 radioimmunotherapy for the treatment of solid cancers1 Sep 2026US 12,721,915 B2Actinium Pharmaceuticals, Inc.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Pim1 inhibitor for treating myeloproliferative neoplasms8 Oct 2026US 2026/0306490 A1Sumitomo Pharma America, Inc.
- Bicyclic heteroarylamides having gpr68 modulating activity8 Oct 2026US 2026/0308159 A1Recursion Pharmaceuticals, Inc.
- 1,3,4-thiadiazol-2-yl carboxamide and 1,3-thiazol-2-yl carboxamide compounds and uses thereof as inhibitors of human polymerase theta1 Oct 2026US 2026/0294921 A1Gilead Sciences, Inc.
- Cell proliferation modulators and uses thereof1 Oct 2026US 2026/0294925 A1Kumquat Biosciences Inc.
Most cited
By later US patents
- Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction140US 6,037,346 AVivus, Inc. · 2000
- Uses of DPP-IV inhibitors107US 8,232,281 B2Boehringer Ingelheim International GmbH · 2012
- Organic compounds93US 8,536,159 B2Intra-Cellular Therapies, Inc. · 2013
- Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction85US 6,127,363 AVivus, Inc. · 2000
- Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles80US 6,811,794 B2Shire Laboratories, Inc. · 2004